Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, toda
HC Wainwright & Co. : The Entera Bio (ENTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The Entera Bio (ENTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
Entera Bio to Present Phase 1 Data From First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it
Entera Bio (ENTX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.05, previous value of -$0.08, and expected value of -$0.06.
Entera Bio (ENTX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.05, previous value of -$0.08, and expected value of -$0.06.
Entera Bio Releases Crucial Financial Information Update
10-Q: Quarterly report
Entera Bio Q1 EPS $0.05 Beats $(0.06) Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.06) by 183.33 percent. This is a 162.5 percent increase over losses of $(0.08)
Entera Bio 1Q EPS 5c >ENTX
Entera Bio 1Q EPS 5c >ENTX
Press Release: Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024.
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
W&T Offshore, Inc. (NYSE: WTI) ("W&T" or the "Company") today reported operational and financial results for the first quarter of 2024 and declared second quarter 2024 dividend of $0.01 per share.
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
Veru, Theravance Biopharma, Adial Pharmaceuticals Among Healthcare Movers
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its
Entera Bio Is Maintained at Buy by HC Wainwright & Co.
Entera Bio Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Entera Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
Entera Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 415.46% HC Wainwright & Co. $10 → $10 Maintains Buy 12/11/2023 415.46% HC Wainwright & Co. → $1
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
No Data